BioStock: PHI “We aim to revolutionize the regenerative medicine market“
A year ago, Patrik Eschricht assumed the role of CEO at PHI, heralding the shift towards regenerative medicine and a commitment to enhancing shareholder value. This transition was further underscored by the entry of private Swiss distributor and investment company Altium as a major shareholder. BioStock talked to Patrik Eschricht to reflect on the past year and explore his vision for the company’s future.
Read the full interview with Patrik Eschricht on biostock.se.
Cell-friendly quality control measures will ensure that future therapies are safe and that such healthcare becomes affordable and accessible to everyone.
Further reading
The latest report by the Alliance for Regenerative Medicine (ARM) offers insightful perspectives for those interested in the emerging technologies that will shape our future regenerative therapies.
